Spinocerebellar Ataxias Clinical Trial Pipeline Analysis: 8+ Key Companies Shaping the Future of Spinocerebellar Ataxias Therapeutics | DelveInsight

DelveInsight's Spinocerebellar Ataxias Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Spinocerebellar Ataxias therapies in various stages of clinical development. The report provides insights into 8+ companies and 10+ pipeline drugs in the Spinocerebellar Ataxias pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Spinocerebellar Ataxias Clinical Trial Landscape Report

• DelveInsight's Spinocerebellar Ataxias pipeline report depicts a developing space with 8+ companies working to develop 10+ pipeline therapies for Spinocerebellar Ataxias treatment.
• Key Spinocerebellar Ataxias companies such as Biohaven Pharmaceuticals, Inc., Steminent US, Inc., Vico Therapeutics B. V., Arrowhead Pharmaceuticals, Neurolixis, Latus Bio, and AAV-CB.
• Promising Spinocerebellar Ataxias pipeline therapies in various stages of development include Troriluzole, Stemchymal, VO659, ARO-ATXN2 Injection|Placebo, NLX-112, and others.

Request a sample and discover the recent advances in Spinocerebellar Ataxias treatment drugs https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Spinocerebellar Ataxias?

Spinocerebellar ataxia (SCA) is a rare, progressive, inherited neurodegenerative disorder that primarily affects the cerebellum but can involve other parts of the central nervous system. It is classified into over 40 subtypes based on genetic loci, with common types including SCA1, SCA2, SCA3, and SCA6.
Spinocerebellar Ataxias are characterized by the loss of voluntary muscle coordination, which can affect gait, speech, and eye movement. Symptoms typically worsen over time and can lead to significant disability. The disease may also affect areas such as the basal ganglia, cortex, and peripheral nerves.
The pathophysiology of Spinocerebellar Ataxia involves genetic mutations, abnormal protein aggregation, mitochondrial dysfunction, and dysregulated cellular processes. Many SCAs are caused by CAG repeat expansions that lead to the production of misfolded proteins called ataxins. Diagnosis involves family history, neurological assessments, imaging, and genetic testing.
There is currently no definitive cure for Spinocerebellar Ataxia, and treatment primarily focuses on alleviating symptoms. Management may include medications for seizures, tremors, and mood disorders, along with physical, occupational, and speech therapy. Emerging research is exploring approaches targeting misfolded mutant proteins, autophagy regulation, and RNA-based therapies.

Emerging Spinocerebellar Ataxias Drug Profiles

Troriluzole: Biohaven Pharmaceuticals, Inc.
Troriluzole is a New Chemical Entity (NCE) and third-generation novel prodrug that modulates glutamate, the most abundant excitatory neurotransmitter in the human body. Its primary mode of action is reducing synaptic levels of glutamate by increasing glutamate uptake from the synapse through enhanced expression and function of excitatory amino acid transporters on glial cells.
In February 2025, Biohaven announced that the U.S. Food and Drug Administration accepted its New Drug Application for troriluzole for the treatment of adult patients with Spinocerebellar Ataxia. In November 2025, Biohaven announced that it had received a Complete Response Letter from the FDA for the NDA seeking approval of VYGLXIA (troriluzole) for Spinocerebellar Ataxia. The drug is included in the Phase III stage of the Spinocerebellar Ataxias pipeline.

Stemchymal: Steminent US, Inc.
Stemchymal is an allogeneic stem cell therapy that uses mesenchymal stem cells isolated from the adipose tissue of healthy individuals. The cells are administered to recipients through intravenous infusion. The therapy has demonstrated therapeutic effects in vivo, with infusion shown to partially restore motor function in SCA mouse models. Stemchymal has also been granted orphan drug designation in Japan. Currently, the drug is in the Phase II stage of development for the treatment of Spinocerebellar Ataxias.

VO659: Vico Therapeutics B. V.
VO659 is a clinical candidate directly targeting the CAG repeat expansion, the mutation that causes all polyglutamine diseases. It is an antisense oligonucleotide (ASO) designed to bind directly to CAG repeats, sterically block translation, and reduce mutant protein in an allele-preferential manner.
The CAG repeat expansion causes nine polyglutamine diseases, including Huntington's disease and various forms of Spinocerebellar Ataxia. VO659 is designed to reduce mutant protein while preserving essential normal gene function. Currently, the drug is in the Phase I/II stage of development for the treatment of Spinocerebellar Ataxias.

Learn more about the novel and emerging Spinocerebellar Ataxias pipeline therapies https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Spinocerebellar Ataxias Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Spinocerebellar Ataxias Companies: Biohaven Pharmaceuticals, Inc., Steminent US, Inc., Vico Therapeutics B. V., Arrowhead Pharmaceuticals, Neurolixis, Latus Bio, AAV-CB
• Key Spinocerebellar Ataxias Pipeline Therapies: Troriluzole, Stemchymal, VO659, ARO-ATXN2 Injection|Placebo, NLX-112, and others.

Dive deep into rich insights for new drugs for Spinocerebellar Ataxias treatment, visit https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Spinocerebellar Ataxias Pipeline Report Introduction
2. Spinocerebellar Ataxias Pipeline Report Executive Summary
3. Spinocerebellar Ataxias Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Spinocerebellar Ataxias Pipeline Therapeutics
6. Spinocerebellar Ataxias Pipeline: Late Stage Products (Phase III)
7. Spinocerebellar Ataxias Pipeline: Mid Stage Products (Phase II)
8. Spinocerebellar Ataxias Pipeline: Early Stage Products (Phase I/II)
9. Spinocerebellar Ataxias Pipeline: Preclinical and Discovery Stage Products
10. Spinocerebellar Ataxias Pipeline Therapeutics Assessment
11. Inactive Products in the Spinocerebellar Ataxias Pipeline
12. Key Companies
13. Key Products in the Spinocerebellar Ataxias Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

For further information on the Spinocerebellar Ataxias pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.